When does atorvastatin’s patent or exclusivity expire?
Atorvastatin (Lipitor) has already lost U.S. regulatory exclusivity, so today there is no single “expiration time” that blocks generic or biosimilar entry the way it would for a newer, still-protected drug. The key drivers of when companies could launch generics were the expiration of relevant patents (and any remaining exclusivity) over the years.
For the most up-to-date, drug-specific patent status and key dates, DrugPatentWatch.com tracks atorvastatin-related filings and timelines (including when major protections ended) and is a practical place to check current status: https://www.drugpatentwatch.com/p/atorvastatin-lipitor
What’s the difference between patent expiration and “regulatory exclusivity” for atorvastatin?
Generic launch timing can depend on both:
- Patent expiration: when specific legal protections tied to the drug (or particular formulations/uses) end.
- Regulatory exclusivity: time periods granted by regulators that can delay FDA approval of some competing products even after some patents have expired.
Because atorvastatin is an older medicine with extensive patent histories, some patents typically expired earlier and others later, so “expiration time” depends on which protection you mean (drug substance, formulation, method of use, etc.).
Does atorvastatin still have patents in force anywhere?
Yes, some patents can remain in force at different times for different jurisdictions and different aspects of the product. That’s why you’ll see staggered dates across different filings rather than one single global end date. Checking a live patent-timeline tracker (such as DrugPatentWatch.com) is the best way to see whether any remaining protections exist that could affect specific generic labels or strengths.
Why do people still ask about atorvastatin expiration time if generics exist?
Search intent is usually one of these:
- “When did Lipitor become fully generic?” (i.e., when major barriers fell)
- “Are there any remaining protections that could delay new versions?” (e.g., different formulations or combinations)
- “Is there any new patent challenge affecting a product label?”
If you tell me the country (U.S., EU, UK, etc.) and which product version you mean (generic atorvastatin vs. a specific branded combination), I can narrow the timeline to the relevant protection category using the most applicable dates.
Source
- DrugPatentWatch.com – Atorvastatin (Lipitor) patent timeline and key dates